Trade Elicit Therapeutics Inc. - ELTX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.3610 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 8.0195 |
| Open | 7.8895 |
| 1-Year Change | 96.97% |
| Day's Range | 7.8895 - 8.7895 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 8.3495 | 0.1600 | 1.95% | 8.1895 | 8.7895 | 7.7995 |
| Feb 20, 2025 | 8.0195 | 0.2400 | 3.09% | 7.7795 | 8.0495 | 7.4895 |
| Feb 19, 2025 | 8.0295 | 0.3300 | 4.29% | 7.6995 | 8.0795 | 7.6995 |
| Feb 18, 2025 | 7.9995 | 0.0000 | 0.00% | 7.9995 | 8.1795 | 7.7495 |
| Feb 14, 2025 | 7.8595 | 0.3700 | 4.94% | 7.4895 | 8.1195 | 7.3895 |
| Feb 13, 2025 | 7.6795 | 0.1900 | 2.54% | 7.4895 | 7.7895 | 7.3895 |
| Feb 12, 2025 | 7.5095 | -0.2300 | -2.97% | 7.7395 | 7.9895 | 7.4995 |
| Feb 11, 2025 | 7.9095 | -0.1500 | -1.86% | 8.0595 | 8.1795 | 7.7795 |
| Feb 10, 2025 | 7.9895 | -0.8200 | -9.31% | 8.8095 | 8.8895 | 7.8895 |
| Feb 7, 2025 | 8.7395 | -0.3000 | -3.32% | 9.0395 | 9.1795 | 8.7395 |
| Feb 6, 2025 | 9.2595 | -0.1800 | -1.91% | 9.4395 | 9.4395 | 9.0495 |
| Feb 5, 2025 | 9.3995 | 0.3000 | 3.30% | 9.0995 | 9.4095 | 8.9895 |
| Feb 4, 2025 | 9.1795 | 0.1900 | 2.11% | 8.9895 | 9.1795 | 8.9395 |
| Feb 3, 2025 | 8.7795 | -0.2100 | -2.34% | 8.9895 | 8.9895 | 8.4895 |
| Jan 31, 2025 | 9.2695 | -0.1200 | -1.28% | 9.3895 | 9.4995 | 8.6595 |
| Jan 30, 2025 | 9.4095 | 1.3200 | 16.32% | 8.0895 | 9.4095 | 7.8295 |
| Jan 29, 2025 | 9.3995 | 0.8100 | 9.43% | 8.5895 | 9.9195 | 8.5895 |
| Jan 28, 2025 | 8.4895 | 0.3900 | 4.82% | 8.0995 | 8.8995 | 8.0895 |
| Jan 27, 2025 | 7.9095 | 0.0600 | 0.76% | 7.8495 | 7.9895 | 7.6995 |
| Jan 24, 2025 | 7.5495 | 0.5000 | 7.09% | 7.0495 | 8.1895 | 7.0495 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Angion Biomedica Corp. Company profile
About Angion Biomedica Corp
Angion Biomedica Corp. is a late-stage biopharmaceutical company. The Company focuses on discovery, development and commercialization of small molecule therapeutics to address acute organ injuries and fibrotic diseases. The Company’s lead product candidate is ANG-3777. Its pipeline includes ANG-3070, rho kinase 2 (ROCK2), and CYP11B2. Its ANG-3777 is a hepatocyte growth factor (HGF) mimetic it is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other organs, such as the lungs, central nervous system (CNS) and heart. It is also evaluating ANG-3777 for indications within acute lung injury (ALI), with focus on acute respiratory distress syndrome (ARDS), as well as acute CNS injuries. The Company’s other programs are for the treatment of fibrotic diseases, ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).
Financial summary
BRIEF: For the nine months ended 30 September 2021, Angion Biomedica Corp revenues decreased 2% to $2.4M. Net loss increased 36% to $69.5M. Revenues reflect Grant revenue decrease from $2.4M to $0K. Higher net loss reflects Research and development - Balancing increase of 40% to $36.9M (expense), Other Non Operati decrease from $10K (income) to $3.6M (expense), Stock-based Compensation in R&D increase from $1.6M to $5.1M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
451 D Street, 5Th Floor
BOSTON
MASSACHUSETTS 02459
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com